Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Follicle Activation Clear all
Completed Phase 3 Interventional

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

NCT00003414
View directory record Official record
Conditions
Graft Versus Host Disease, Lymphoma
Interventions
aldesleukin, recombinant interferon gamma, busulfan, cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2015 · Synced Sep 10, 2026, 5:50 AM EDT
Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

NCT06667687
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
ABBV-291
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Huntersville, North Carolina • Eugene, Oregon • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 10, 2026, 5:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Hormone Induced Effects on Ligament Laxity and Lower Extremity Motor Control

NCT04055129
View directory record Official record
Conditions
Hormone Influence on Ligament Laxity and Motor Control
Interventions
No interventions
Other
Lead sponsor
University of St. Augustine for Health Sciences
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Marcos, California
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 10, 2026, 5:50 AM EDT
Recruiting Phase 1 Interventional

A Study of ARC-02 in B-cell NHL

NCT07691606
View directory record Official record
Conditions
B-cell Non Hodgkin Lymphoma
Interventions
ARC-02, Rituximab
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Los Angeles, California • Louisville, Kentucky • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 10, 2026, 5:50 AM EDT
Terminated Phase 1 Interventional Results available

Rituximab + Immunotherapy in Follicular Lymphoma

NCT03636503
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Rituximab, Utomilumab, Avelumab, PF04518600
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Duarte, California • New Haven, Connecticut • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2025 · Synced Sep 10, 2026, 5:50 AM EDT
Recruiting Not applicable Interventional

Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors

NCT07545837
View directory record Official record
Conditions
Thyroid Gland Follicular Carcinoma, Thyroid Gland Papillary Carcinoma
Interventions
Counseling, Interview, Questionnaire Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 10, 2026, 5:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00245037
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
Interventions
therapeutic allogeneic lymphocytes, busulfan, cyclosporine, fludarabine phosphate, mycophenolate mofetil, peripheral blood stem cell transplantation, Total Body Irradiation (TBI), Granulocyte colony-stimulating factor (G-CSF), Phenytoin, Methotrexate
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Sep 10, 2026, 5:50 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma

NCT00244946
View directory record Official record
Conditions
Lymphoma
Interventions
therapeutic autologous lymphocytes, carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation (PBSCT)
Biological · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
15 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Sep 10, 2026, 5:50 AM EDT
Recruiting Phase 1 Interventional

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

NCT05010005
View directory record Official record
Conditions
T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Interventions
Ruxolitinib, Duvelisib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Miami, Florida • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 5:50 AM EDT
Terminated Not applicable Interventional

In Vitro Follicle Activation

NCT02496598
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Infertility
Interventions
In Vitro Follicle Activation (IVA), Follicle Activation
Procedure · Drug
Lead sponsor
National Foundation for Fertility Research
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 10, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

NCT00027937
View directory record Official record
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
aldesleukin, filgrastim, sargramostim, busulfan, cyclophosphamide, melphalan, paclitaxel, thiotepa, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 56 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Sep 10, 2026, 5:50 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Assessing the Effects of Hormones on Noninvasive Transcranial Stimulation

NCT07635017
View directory record Official record
Conditions
Cortical Excitability, Healthy, TMS, Menstrual Cycle, Menopause
Interventions
Transcranial Electrical Stimulation, Transcranial Magnetic Stimulation, TES + TMS
Device
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years to 40 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 10, 2026, 5:50 AM EDT
Recruiting No phase listed Observational

The Effect of the Menstrual Cycle on Immune Cell Activity and Recovery After Resistance Exercise

NCT06985420
View directory record Official record
Conditions
Healthy Women, Menstruation, Resistance Exercise
Interventions
Resistance exercise, Menstrual Cycle Phases
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 10, 2026, 5:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Inovium Ovarian Rejuvenation Trials

NCT03178695
View directory record Official record
Conditions
Perimenopausal Disorder, Menopause, Menopause, Premature, Menopause Related Conditions, Menopause Premature Symptomatic, Menopause Premature Asymptomatic, Premature Ovarian Failure, Premature Ovarian Failure, Familial, Premature Ovarian Failure 2A, Premature Ovarian Failure 3, Premature Ovarian Failure 4, Premature Ovarian Failure 1, Premature Ovarian Failure 5, Premature Ovarian Failure 6, Premature Ovarian Failure 7, Premature Ovarian Failure 9, Premature Ovarian Failure 8, Infertility, Infertility, Female, Infertility Unexplained
Interventions
Autologous PRP injection into human ovarian tissue
Other
Lead sponsor
Ascendance Biomedical
Industry
Eligibility
35 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2020 · Synced Sep 10, 2026, 5:50 AM EDT